论文部分内容阅读
对新诊断未曾治疗过的肥胖型2型糖尿病患者给予12周甘精胰岛素联合二甲双胍缓释片治疗。观察胰岛细β胞功能变化,空腹,餐后2小时血糖达标情况,体重指数。结果β细胞功能获得显著改善(P<0.01),空腹,餐后2小时血糖快速达标,体重及体重指数下降。结论甘精胰岛素联合二甲双胍缓释片治疗新诊断肥胖型2型糖尿病不但能显著改善β细胞功能⑴⑵。空腹,餐后2小时血糖快速达标,体重及体重指数下降。而且减轻了患者用药次数及用药负担。停药后已恢复的细β胞功能可维持4月~4年或更长。
Patients with newly diagnosed, untreated, obese type 2 diabetes were given 12-week insulin glargine and metformin extended-release tablets. Observation of pancreatic β-cell function changes, fasting, 2-hour postprandial blood glucose compliance, body mass index. Results β-cell function was significantly improved (P <0.01), fasting, fasting blood glucose 2 hours postprandial, body weight and body mass index decreased. Conclusion Glargine and metformin sustained-release tablets in the treatment of newly diagnosed obese type 2 diabetes can not only significantly improve β-cell function ⑴ ⑵. Fasting, 2 hours postprandial blood glucose rapid compliance, weight and body mass index decreased. And reduce the number of patients medication and medication burden. Fine beta cell function restored after discontinuation can be maintained for 4 months to 4 years or longer.